首页> 外文期刊>Chemistry: A European journal >Advances in platinum chemotherapeutics
【24h】

Advances in platinum chemotherapeutics

机译:铂化学治疗学的进展

获取原文
获取原文并翻译 | 示例
           

摘要

The approved platinum(II)-based anticancer agents cisplatin, carboplatin and oxaliplatin are widely utilised in the clinic, although with numerous disadvantages. With the aim of circumventing unwanted side-effects, a great deal of research is being conducted in the areas of cancer-specific targeting, drug administration and drug delivery. The targeting of platinum complexes to cancerous tissues can be achieved by the attachment of small molecules with biological significance. In addition, the administration of platinum complexes in the form of platinum(IV) allows for intracellular reduction to release the active form of the drug, cisplatin. Drug delivery includes such technologies as liposomes, dendrimers, polymers and nanotubes, with all showing promise for the delivery of platinum compounds. In this paper we highlight some of the recent advances in the field of platinum chemotherapeutics, with a focus on the technologies that attempt to utilise the cytotoxic nature of cisplatin, whilst improving drug targeting to reduce side-effects.
机译:尽管许多缺点很多,但已批准的基于铂(II)的抗癌药顺铂,卡铂和奥沙利铂在临床上得到了广泛应用。为了避免有害的副作用,正在针对癌症的靶向,药物管理和药物输送领域进行大量研究。铂络合物对癌组织的靶向可通过附着具有生物学意义的小分子来实现。另外,以铂(IV)形式的铂络合物的施用允许细胞内还原以释放药物的活性形式顺铂。药物输送包括脂质体,树状聚合物,聚合物和纳米管等技术,所有这些都显示出了铂化合物输送的希望。在本文中,我们重点介绍了铂化学治疗领域的一些最新进展,重点是试图利用顺铂的细胞毒性,同时改善靶向药物的作用以减少副作用的技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号